Gubra A/S

GUBRA

Equity

ISIN DK0062266474 / Valor 125706804

Nasdaq Copenhagen Equities (2024-09-16)

DKK 530.00+4.33%

Gubra A/S
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Gubra A/S is a specialized company focusing on high-end preclinical contract research and peptide-based drug discovery, particularly within the realms of metabolic and fibrotic diseases. Utilizing advanced models and technologies, Gubra provides rapid and high-quality data through its comprehensive services. The company’s light-sheet microscopy platform enables 3D imaging of organs in mice and rats, while its automated imaging pipeline and AI-driven image analysis ensure precise drug distribution mapping and histological quantification. Gubra offers a range of histology services, including core histology, multiplex immunohistochemistry, RNAScope®, and unbiased stereology analysis. Additionally, the company provides specialized models for cardiovascular diseases, such as hypertension-induced heart failure and atherosclerosis, complemented by state-of-the-art echocardiography and quantitative whole-heart 3D histology. Gubra also excels in peptide drug discovery, leveraging its AI-driven streaMLine platform to develop clinical-ready drug candidates with robust intellectual property protection. The company’s expertise spans linear, cyclic, disulfide-rich peptides, and peptide drug-conjugates, facilitating the transition from target identification to in vivo target validation.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Gubra A/S reported a significant increase in revenue for the fiscal year 2023. The company's total revenue reached DKK 205 million, up from DKK 199 million in 2022. This growth was driven by strong performance in both the Contract Research Organization (CRO) and Discovery & Partnerships (D&P) segments.

Adjusted EBIT

For the year 2023, Gubra A/S's adjusted EBIT was reported at a loss of DKK 34 million, compared to a profit of DKK 19 million in 2022. The decline in adjusted EBIT was primarily due to increased investments in R&D and the expansion of their facilities and workforce.

Profit/Loss

Gubra A/S experienced a net loss of DKK 44 million for the year 2023, a significant drop from a net profit of DKK 4 million in 2022. The loss was attributed to higher operational costs and strategic investments aimed at long-term growth.

Cash Flows

In 2023, Gubra A/S reported negative cash flows from operating activities amounting to DKK 49 million, compared to a positive cash flow of DKK 24 million in 2022. The negative cash flow was mainly due to increased operational expenses and investments in new projects.

Financial Outlook

Looking ahead to 2024, Gubra A/S has provided guidance for 10-15% organic revenue growth in the CRO business. The company also aims to continue building its R&D pipeline and advance partnership discussions, with a focus on completing the ongoing Phase 1 trial for GUBamy by mid-2024.

Summarized from source with an LLMView Source

Key figures

357%1Y

%3Y

%5Y

Performance

71.2%1Y

64.6%3Y

64.6%5Y

Volatility